96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

85 trials found

diseases per page:

Showing 1 to 10 of 85 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05470985 (ClinicalTrials.gov)	March 10, 2023	12/7/2022	A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimodin Pediatric Participants ...	A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacok ...	Crohn Disease	Drug: Ozanimod	Bristol-Myers Squibb	NULL	Recruiting	2 Years	17 Years	All	120	Phase 2/Phase 3	United States;Australia;Belgium;Canada;Hungary;Poland;Spain;United Kingdom
2	EUCTR2017-004294-14-FR (EUCTR)	02/12/2019	09/02/2018	Multicenter Study of Oral Ozanimodas Maintenance Therapy in patients with Moderately to Severely Act ...	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimodas Mainte ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	535	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
3	EUCTR2017-004293-33-FR (EUCTR)	12/11/2019	09/02/2018	Multicenter Study of Oral Ozanimodas Induction Therapy in patients with Moderately to Severely Activ ...	Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of O ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	675	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Serbia;Portugal;United States;Saudi Arabia;Hong Kong;Slovakia;Greece;Spain;Ukraine;Russian Federatio ...
4	EUCTR2017-004292-31-FR (EUCTR)	05/11/2019	09/08/2019	Multicenter Study of Oral Ozanimodas Induction Therapy in patients with Moderately to Severely Activ ...	Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of O ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	675	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Belarus;United States;Taiwan;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;Franc ...
5	EUCTR2017-004295-55-FR (EUCTR)	08/10/2019	09/02/2018	Multicenter Extension Study of Oral Ozanimodin patients with Moderately to Severely Active Crohn’s D ...	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimodfor Moderately to Severely Active ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1350	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
6	EUCTR2017-004294-14-RO (EUCTR)	11/04/2019	12/05/2022	Multicenter Study of Oral Ozanimodas Maintenance Therapy in patients with Moderately to Severely Act ...	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimodas Mainte ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	485	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
7	EUCTR2017-004295-55-PT (EUCTR)	04/02/2019	01/10/2018	Multicenter Extension Study of Oral Ozanimodin patients with Moderately to Severely Active Crohn’s D ...	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimodfor Moderately to Severely Active ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1200	Phase 3	Portugal;Belarus;Hong Kong;Taiwan;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
8	EUCTR2017-004292-31-RO (EUCTR)	04/02/2019	25/02/2022	Multicenter Study of Oral Ozanimodas Induction Therapy in patients with Moderately to Severely Activ ...	Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of O ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	United States;Belarus;Taiwan;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;Franc ...
9	EUCTR2017-004295-55-BE (EUCTR)	13/12/2018	30/03/2018	Multicenter Extension Study of Oral Ozanimodin patients with Moderately to Severely Active Crohn’s D ...	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimodfor Moderately to Severely Active ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1200	Phase 3	Belarus;Portugal;Hong Kong;Taiwan;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
10	EUCTR2017-004294-14-DK (EUCTR)	30/11/2018	27/08/2018	Multicenter Study of Oral Ozanimodas Maintenance Therapy in patients with Moderately to Severely Act ...	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimodas Mainte ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063 (equivalent to ozanimodHCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Not Recruiting			Female: yes Male: yes	535	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...

First Previous1 2 3 4 5…9Next Last